Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Homoharringtonine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omacetaxine Mepesuccinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 05, 2014
Lead Product(s) : Homoharringtonine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Homoharringtonine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate
Details : Omacetaxine Mepesuccinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hematologic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 01, 2013
Lead Product(s) : Homoharringtonine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable